Moderna Pays Up to $2.25 Billion to End COVID Vaccine Patent War

Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.